Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men

BJU International

Volumn 96, Issue 3, 2005, Pages 308-312

  Kehinde, Elijah O ^a   Mojiminiyi, Olusegun A ^a   Sheikh, Mehraj ^a   Al Awadi, Kaleel A ^a   Daar, Abdallah S ^b   Al Hunayan, Adel ^a   Anim, Jehoram T ^a   Al Sumait, Aisha A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Arab; Asian; Caucasian; Prostate volume; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARAB; ARTICLE; ASIAN; CAUCASIAN; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIGITAL RECTAL EXAMINATION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMAGE ANALYSIS; JAPAN; KUWAIT; MALE; NORMAL HUMAN; OMAN; PRIORITY JOURNAL; PROSTATE; REFERENCE VALUE; TRANSRECTAL ULTRASONOGRAPHY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ARABS; HUMANS; KUWAIT; MALE; MIDDLE AGED; OMAN; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 23244452167     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05620.x     Document Type: Article

References (26)

1. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer Incidence in Five Continents, Vol. VII, no. 143. Lyons, France: IARC Scientific Publications, 1997: 5-9
2. Memon A, AI Muhanna AN. Annual cancer incidence in Kuwaitis 1992-93. In Parkin, DM, Whelan, SL, Ferlay, J Raymond L, Young J, eds. Cancer Incidence in Five Continents, Vol. VII, no. 143. Lyons, France: IARC Scientific Publications 1997: 410-7
3. Kehinde EO. Prostate cancer in Middle East: Perspective From Oman. In Belldegrun A, Kirby RS, Oliver RTD eds. New Perspectives in Prostate Cancer. Oxford: Isis Medical Media, 1998: 383-90
4. Hanash KA, Al-Othaimeen A, Kattan S et al. Prostatic carcinoma: a nutritional disease? Conflicting data from the Kingdom of Saudi Arabia. J Urol 2000; 164: 1570-2
5. Oesterling JE, Kumamoto Y, Tsukamoto T et al. Serum PSA in a community-based population of healthy Japanese men: lower values than for similarly aged White men. Br J Urol 1995; 75: 347-53
6. Polascik TJ, Oesterling JE, Partin WA. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999; 162: 293-306
7. Pruthi RS. The dynamics of prostate-specific antigen in benign and malignant diseases of the prostate. BJU Int 2000; 86: 652-8
8. Petitclere C. Approval recommendation on the theory of reference values Part 2. Selection of individuals for the production of reference values. J Clin Chem Clin Biochem 1987; 25: 639-44
9. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4
10. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 1993; 150: 1837-9
11. Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M. Relationship between prostate specific antigen, prostate volume, and age in the benign prostate. Br J Urol 1993; 71: 445-50
12. He D, Wang M, Chen X et al. Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population. Urology 2004; 63: 722-6
13. Jacobsen SJ, Klee GG, Lilja H, Wright GL Jr, Oesterling JE. Stability of serum prostate-specific antigen determination across laboratory, assay and storage time. Urology 1995; 45: 447-53
14. Junker R, Brandt B, Zechel C, Assman G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem 1997; 43: 1588-94
15. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
16. Akazaki K, Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst 1973; 50: 1137-44
17. Breslow NC, Chan CW, Dhom G et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20: 680-8
18. Anim JT, Ibrahim BH, Sattar SA, Sarkar C. Benign disorders of the prostate: a histopathological study. Ann Saudi Med 1998; 18: 22-7
19. Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schroder FH. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who have no evidence of disease at initial screening. Cancer 2005; 103: 242-50
20. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996; 48 (Suppl. 6A): 55-61
21. Ornstein DK, Smith DS, Humphrey PA, Catalona WJ. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 1998; 159: 1234-7
22. Lein M, Koenig F, Jung K et al. The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol 1998; 82: 231-6
23. Oesterling JE, Jacobsen SJ, Klee GG et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090-5
24. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentration of 2.6-4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5
25. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percentage free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998; 159: 1238-42
26. Carter HB, Partin AW, Luderer AA et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer adecade before diagnosis. Urology 1997; 49: 379-84